Copyright
©The Author(s) 2017.
World J Meta-Anal. Oct 26, 2017; 5(5): 124-131
Published online Oct 26, 2017. doi: 10.13105/wjma.v5.i5.124
Published online Oct 26, 2017. doi: 10.13105/wjma.v5.i5.124
Table 2 Summary of included studies
| Study/yr | Intervention | Control | Remission (intervention/control) | Response (intervention/control) | Adverse effects (intervention/control) |
| Luo/2008 | Thalidomide100 mg/d | SASP | 6/5 | 15/13 | 10/9 |
| 4 g/d | |||||
| Lazzerini/2013 | Thalidomide 50, 100 and 150 mg/d | Unknown | 3/13 | 5/5 | Unknown/1 |
| Mansfield/2007 | lenalidomide 25 mg ⁄d, | Unknown | 2/7 | 4/4 | 10/18 |
| lenalidomide 5 mg ⁄d | 10/7 | 6/4 | 12/10 |
- Citation: Sami Ullah KR, Xiong YL, Miao YL, Ummair S, Dai W. Thalidomide and thalidomide analogues in treatment of patients with inflammatory bowel disease: Meta-analysis. World J Meta-Anal 2017; 5(5): 124-131
- URL: https://www.wjgnet.com/2308-3840/full/v5/i5/124.htm
- DOI: https://dx.doi.org/10.13105/wjma.v5.i5.124